Clovis Oncology Inc (CLVS.xnas)

traders view logo Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

Clovis Oncology Inc (CLVS.xnas) Profile

Clovis Oncology Inc (CLVS.xnas) is a commercial-stage biotechnology company headquartered in Colorado, America. Clovis is focusing on acquiring, developing and commercialising innovative anti-cancer treatments across the United States but also in Europe and other international markets and employs 429 people. Clovis’ product development programs target specific subsets of cancer and seek to develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. The company’s appropriate technology for each program, and expertise gained regulatory approvals and support internationally commercialisation that parallels Clovis’ regulatory and commercialisation paths. Clovis Oncology Inc stock (CLVS.xnas) is listed on NASDAQ, had a market capitalisation of $350.94M (USD) as of December 2021 and $165M (USD) in 2020 yearly revenues. Clovis Oncology’s only approved product Rubraca reported sales of $74.9M (USD) and holds bright prospects for the ovarian cancer market. Clovis is also evaluating Rubraca in several label expansion studies across ovarian cancer is being evaluated in a phase III ATHENA study, both as a monotherapy and in combination with Bristol Myers’ BMY Opdivo in advanced ovarian cancer as a first-line maintenance treatment and data from this study is expected in 2022.

Holding cost
Long
-5%
Short
-2.5%
Trading hours in US Eastern Time
Fri
16:30-23:00
Mon
16:30-23:00
Tue
16:30-23:00
Wed
16:30-23:00
Thu
16:30-23:00
Sun
Closed
Sat
Closed

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

Why Trade Clovis Oncology Inc (CLVS.xnas) with FP Markets? An Australian-regulated forex & CFD broker
go long or short
Go Long or Short

Increase your ability to profit in
all market conditions
Leverage options up to 20:1

direct market access
Direct Market Access (DMA) Execution

Real-time, transparent share prices
Control, Functionality and deep liquidity
Full Market depth & see your orders in the queue

advanced platforms
Advanced Platforms
& Technology

MT4, MT5, Webtrader & Iress with
superior client portal

24/5 Multilingual customer support
24/5 Multilingual
Customer Support

Award winning support &
personal account managers

global exposure
Global Exposure

Low margins and competitive commission
+10,000 products on global stocks
across 4 continents

earn dividends
Earn Dividends

On long positions
No ownership of physical
shares necessary

Start Trading
in Minutes

bullet Access 10,000+ financial instruments
bullet Auto open & close positions
bullet News & economic calendar
bullet Technical indicators & charts
bullet Many more tools included

By supplying your email you agree to FP Markets privacy policy and receive future marketing materials from FP Markets. You can unsubscribe at any time.




Source - database | Page ID - 17530

Get instant Updates in Telegram